Ultrasound and Proteomics for Guselkumab Response Assessment in Crohn's Disease (UPGRADE).
Recruiting
Observational Study
Crohn's Disease of Both Small and Large Intestine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 90 (estimated)
- Sponsor
- University of Calgary · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to evaluate the response of guselkumab in adult patients with Crohn's disease (CD) as measured on intestinal ultrasound (IUS), the relative quantities of CD64 in endoscopic tissue biopsies, and the protein signature in the blood of patients with and without therapy response. The main question it aims to answer is:
* What is the proportion of ileal Crohn's d…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Male or female, 18 to 80 years old
BWT on IUS \> 3.0mm in the ileum and colonic disease permitted.
Patients naïve to guselkumab.
Stricture phenotype - BWT \> 3 mm, luminal apposition \< 1cm or \< 50% of adjacent normal bowel diameter, and prestenotic dilation of distal ileum.…